atrial fibrillation and stroke prevention - Continuing Medical ...
atrial fibrillation and stroke prevention - Continuing Medical ... atrial fibrillation and stroke prevention - Continuing Medical ...
Essentials in Primary Care Conference Wednesday, July 31, 2013 Dabigatran Dosing • Dosing with normal renal function 150mg PO b.i.d with or without food. swallow capsules whole • Renal impairment: • CrCL 15-30 mL/min : 75mg b.i.d. • CrCL 30 Start parenteral anticoagulant 12 hrs after the last dose of dabigatran < 30 Start parenteral anticoagulant 24 hours after the last dose of dabigatran Dabigatran Package Insert Jan Basile, MD Atrial Fibrillation & Stroke Prevention
Essentials in Primary Care Conference Wednesday, July 31, 2013 Time to Stroke or Systemic Embolism: Dabigatran vs. warfarin, stratified by center-based time-in-range (TTR) Wallentin et al. Lancet 2010. 376:975-83 Differences in Major Outcomes in RE-LY and RELY-ABLE RE-LY patients (n=18,113) Dabigatran Dabigatran HR p-value 150 mg bid 110 mg bid stroke (/yr) 1.0% 1.4% 0.70 (0.56–0.89) 0.003 major bleeding (/yr) 3.1 % 2.7 % 1.16 (1.00-1.34) 0.05 RELY-ABLE patients (N=5,671 stroke (/yr) 1.2 % 1.4 % 0.89 (0.66-1.21) n.a. major bleeding (/yr) 3.8 % 3.0 % 1.26 (1.04-1.53) n.a. Connolly SJ, et al.The long term multi-center observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation. 2013;128:XX-XXX. Jan Basile, MD Atrial Fibrillation & Stroke Prevention
- Page 1 and 2: Essentials in Primary Care Conferen
- Page 3 and 4: Essentials in Primary Care Conferen
- Page 5 and 6: Essentials in Primary Care Conferen
- Page 7 and 8: Essentials in Primary Care Conferen
- Page 9 and 10: Essentials in Primary Care Conferen
- Page 11 and 12: Essentials in Primary Care Conferen
- Page 13 and 14: Essentials in Primary Care Conferen
- Page 15 and 16: Essentials in Primary Care Conferen
- Page 17 and 18: Essentials in Primary Care Conferen
- Page 19 and 20: Essentials in Primary Care Conferen
- Page 21 and 22: Essentials in Primary Care Conferen
- Page 23 and 24: Essentials in Primary Care Conferen
- Page 25 and 26: Essentials in Primary Care Conferen
- Page 27: Essentials in Primary Care Conferen
- Page 31 and 32: Essentials in Primary Care Conferen
- Page 33 and 34: Essentials in Primary Care Conferen
- Page 35 and 36: Essentials in Primary Care Conferen
- Page 37 and 38: Essentials in Primary Care Conferen
- Page 39 and 40: Essentials in Primary Care Conferen
- Page 41 and 42: Essentials in Primary Care Conferen
- Page 43 and 44: Essentials in Primary Care Conferen
Essentials in Primary Care Conference<br />
Wednesday, July 31, 2013<br />
Time to Stroke or Systemic Embolism:<br />
Dabigatran vs. warfarin, stratified by center-based<br />
time-in-range (TTR)<br />
Wallentin et al. Lancet 2010. 376:975-83<br />
Differences in Major Outcomes<br />
in RE-LY <strong>and</strong> RELY-ABLE<br />
RE-LY patients<br />
(n=18,113)<br />
Dabigatran Dabigatran HR p-value<br />
150 mg bid 110 mg bid<br />
<strong>stroke</strong> (/yr) 1.0% 1.4% 0.70 (0.56–0.89) 0.003<br />
major bleeding (/yr) 3.1 % 2.7 % 1.16 (1.00-1.34) 0.05<br />
RELY-ABLE patients<br />
(N=5,671<br />
<strong>stroke</strong> (/yr) 1.2 % 1.4 % 0.89 (0.66-1.21) n.a.<br />
major bleeding (/yr) 3.8 % 3.0 % 1.26 (1.04-1.53) n.a.<br />
Connolly SJ, et al.The long term multi-center observational study of dabigatran treatment in<br />
patients with <strong>atrial</strong> <strong>fibrillation</strong> (RELY-ABLE) study. Circulation. 2013;128:XX-XXX.<br />
Jan Basile, MD<br />
Atrial Fibrillation & Stroke Prevention
Change language